Leaders in Biopharma Discuss Innovations at Veeva R&D and Quality Summit in Madrid
The Veeva R&D and Quality Summit, scheduled for June 4-5 in Madrid, promises to be a pivotal event for the biopharmaceutical world. Hosted by Veeva Systems, a frontrunner in cloud-based software solutions for life sciences, the summit aims to gather over 1,400 industry professionals to delve into the latest developments in drug development, regulatory advancements, and quality assurance.
A lineup of esteemed keynote speakers is set to highlight the event, including representatives from major companies like Bayer, Lonza, Merck Sharp & Dohme (MSD), Novo Nordisk, Recipharm, and Teva. Each speaker will discuss how their organizations leverage connected platforms and AI technologies to enhance the efficiency and effectiveness of drug development processes.
One of the key presentations will feature Veeva AI, a transformative initiative aimed at integrating artificial intelligence into the Veeva Vault Platform and its applications. This initiative seeks to automate crucial functions and improve productivity significantly, addressing the ever-growing need for innovation in the industry.
Throughout the summit, attendees can participate in more than 100 sessions covering diverse topics including clinical operations, safety protocols, regulatory compliance, and quality management. The collaborative environment of the summit allows executives to exchange insights, formulate strategic partnerships, and discuss best practices essential for navigating the challenges of drug development.
Bayer will share insights on optimizing its clinical infrastructure through a customer-focused collaborative model. Lonza, as a leading Contract Development and Manufacturing Organization (CDMO), will discuss how the evolving industry ecosystem is transforming quality management practices amongst partners. MSD is expected to elaborate on its revamped pharmacovigilance processes and efficiency improvements through robust data foundations.
Novo Nordisk will explain how they are expediting clinical trials and product launches by aligning business and IT functions on the Veeva Development Cloud, thus enhancing collaboration, automation, and data consistency. Teva will showcase its adaptive strategies for regulatory changes, emphasizing innovation and a data-driven mindset as critical components for improving operational efficiency.
"Fresh thinking and a strong community are essential for transforming the way we deliver medications to patients," stated Rik Van Mol, Senior Vice President of R&D and Quality. The summit aims to foster an environment where leaders can brainstorm innovative ideas, share breakthroughs, and collectively shape the future landscape of the biopharma industry.
The Veeva R&D and Quality Summit is an exclusive event designed specifically for life sciences professionals. Those interested in participating can register and view the full agenda by visiting veeva.com/eu/Summit. Veeva Systems remains steadfast in its commitment to product innovation, quality, and the success of its clients across the biopharmaceutical spectrum, serving more than 1,000 customers globally, from the largest companies to emerging biotech firms.
As Veeva continues to prioritize the alignment of stakeholder interests—including customers, employees, shareholders, and the industries they operate in—this summit serves as a crucial touchpoint for the advancement of the biopharma field. Veeva's outlook underscores its mission as a Public Benefit Corporation, emphasizing its dedication to driving beneficial changes within the healthcare landscape and leveraging technology for the common good.
In conclusion, the gathering of biopharma leaders at the Veeva R&D and Quality Summit illustrates a collective commitment to innovation and collaboration in addressing the ongoing challenges in drug development. This summit not only enhances networking opportunities but also sets the stage for groundbreaking discussions that could redefine the future of biopharmaceuticals.